MARKET

PRTK

PRTK

Paratek Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.74
-0.50
-8.01%
Opening 15:55 09/23 EDT
OPEN
6.20
PREV CLOSE
6.24
HIGH
6.21
LOW
5.66
VOLUME
759.38K
TURNOVER
--
52 WEEK HIGH
6.72
52 WEEK LOW
2.500
MARKET CAP
260.52M
P/E (TTM)
-1.9119
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 5d ago
Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance
Paratek has developed 2 antibiotics treatments - Nuzyra and Seysara - to treat different types of skin conditions.The company out-licenses Seysara marketing & sales but has launched Nuzyra itself - initial sales have been impressive - >10% qoq increase to $8.1m in Q220.The peak sales opportunity could be >$400m which makes Paratek - currently trading at $5.9 - an attractive investment opportunity.The company has a 5-year partnership in place with BARDA worth ~$285m, which will help it cover costs in a challenging market. Currently, the company is heavily loss-making.Going all in on antibiotics is risky, but Paratek may well have the experience and backing to be successful. I am bullish.
Seekingalpha · 5d ago
Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and
GlobeNewswire · 09/09 21:01
Billionaire David Shaw Pours Money Into 3 Strong Buy Stocks
Are the tides turning on Wall Street? Stocks fell for a third consecutive session, as investors abandoned the tech heavyweights that have been at the forefront of the market’s remarkable charge forward. What’s behind the sell-off? Sky-high valuations reminiscent of the dot-com era have sparked fears
TipRanks · 09/09 14:36
Market Sentiment Around Loss-Making Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
We feel now is a pretty good time to analyse Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) business as it appears the...
Simply Wall St. · 08/25 15:17
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 12:45
Recap: Paratek Pharmaceuticals Q2 Earnings
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 48.04% over the past year to ($0.53), which may not compare to the estimate of ($0.06).Revenue of
Benzinga · 08/10 12:12
Paratek Pharmaceuticals Raises FY20 Sales guidance From $75M-$80M vs $78M-$83M vs $81.16M Est.
Benzinga · 08/10 11:42
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTK. Analyze the recent business situations of Paratek Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTK stock price target is 15.00 with a high estimate of 34.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 30.25M
% Owned: 66.65%
Shares Outstanding: 45.39M
TypeInstitutionsShares
Increased
35
2.84M
New
33
412.86K
Decreased
26
745.43K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.22%
Pharmaceuticals & Medical Research
-1.31%
Key Executives
Chairman/Director
Michael Bigham
Chief Executive Officer/Chief Compliance Officer/Director
Evan Loh
Chief Financial Officer/Chief Accounting Officer
Sarah Higgins
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
William Haskel
Vice President
Adam Woodrow
Director
Rolf Hoffman
Other
Randall Brenner
Director
Rolf Hoffmann
Independent Director
Thomas Dietz
Independent Director
Timothy Franson
Independent Director
Kristine Peterson
Independent Director
Robert Radie
Independent Director
Jeffrey Stein
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 1.33
06/04/2014
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRTK
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.